Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer

Gynecologic Oncology

Volumn 68, Issue 3, 1998, Pages 267-273

  Recio, Fernando O ^a   Piver, M Steven ^a   Hempling, Ronald E ^a   Driscoll, Deborah L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYTARABINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PERITONEAL CATHETER; PERITONITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032031730     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.4940     Document Type: Article

References (12)

1. Alberts D S, Liu P Y, Hannigan E V, O'Toole R, Williams S D, Young J A, Franklin E W, Clarke-Pearson D L, Malviya V K, DuBeshter B, Adelson M D, Hoskins W S. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955.
2. Piver M S, Lele S B, Marchetti D L, Baker T R, Emrich L J, Hartman A B. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol. 6:1988;1679-1684.
3. Piver M S, Recio F O, Baker T R, Driscoll D. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer. 73:1994;1693-1698.
4. WHO Handbook for Reporting Results of Cancer Treatment. 1979;World Health Organization, Geneva.
5. Kaplan E L, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
6. Piver M S, Fanning J, Craig K A. Ovarian Cancer. Gynecologic Oncology. 1993;McGraw-Hill, New York. p. 250-292.
7. McGuire W P, Rowinsky E K, Rosenshein N B, Grumbine F C, Ettinger D S, Armstrong D K. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 111:1989;273-279.
8. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med. 334:1996;1-6.
9. Howell S B, Zimm S, Markman M, Abramson I S, Cleary S, Lucas W E, Weiss R J. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 5:1987;1607-1612.
10. Markman M, Reichman B, Hakes T, Lewis J L, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol. 10:1992;1479-1484.
11. Neijt J P, tenBokkel Huinink W W, Vanderburg M EL, van Oosterom A T, Willemse P HB, Vermorken J P, van Lindert A CM, Heintz A PM, Aartsen E, vanLent M, Trimbos J B, Meijer A J. Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for ovarian cancer. Eur J Cancer. 27:1991;1367-1372.
12. Baker T R, Piver M S, Hempling R E. Long-term survival by cytoreductive surgery to <1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian adenocarcinoma. Cancer. 74:1994;656-663.